HomeCompareNRBO vs PEP

NRBO vs PEP: Dividend Comparison 2026

NRBO yields 84.75% · PEP yields 3.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NRBO wins by $1.90M in total portfolio value
10 years
NRBO
NRBO
● Live price
84.75%
Share price
$2.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.05M
Annual income
$615,863.14
Full NRBO calculator →
PEP
PepsiCo Inc.
● Live price
3.66%
Share price
$155.29
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$144.7K
Annual income
$63,430.49
Full PEP calculator →

Portfolio growth — NRBO vs PEP

📍 NRBO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNRBOPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NRBO + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NRBO pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NRBO
Annual income on $10K today (after 15% tax)
$7,203.39/yr
After 10yr DRIP, annual income (after tax)
$523,483.67/yr
PEP
Annual income on $10K today (after 15% tax)
$311.45/yr
After 10yr DRIP, annual income (after tax)
$53,915.92/yr
At 15% tax rate, NRBO beats the other by $469,567.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NRBO + PEP for your $10,000?

NRBO: 50%PEP: 50%
100% PEP50/50100% NRBO
Portfolio after 10yr
$1.10M
Annual income
$339,646.82/yr
Blended yield
31.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

NRBO
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-20.1
Piotroski
0/9
PEP
Analyst Ratings
1
Strong
15
Buy
28
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+11.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NRBO buys
0
PEP buys
0
No recent congressional trades found for NRBO or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNRBOPEP
Forward yield84.75%3.66%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$2.05M$144.7K
Annual income after 10y$615,863.14$63,430.49
Total dividends collected$1.79M$125.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: NRBO vs PEP ($10,000, DRIP)

YearNRBO PortfolioNRBO Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$19,175$8,474.58$10,854$514.44+$8.3KNRBO
2$35,703$15,186.58$11,982$758.21+$23.7KNRBO
3$64,630$26,427.72$13,526$1,136.44+$51.1KNRBO
4$113,864$44,709.84$15,727$1,741.93+$98.1KNRBO
5$195,450$73,615.70$19,012$2,750.28+$176.4KNRBO
6$327,228$118,096.19$24,173$4,514.44+$303.1KNRBO
7$534,919$184,784.73$32,789$7,793.80+$502.1KNRBO
8$854,669$282,305.61$48,258$14,354.51+$806.4KNRBO
9$1,336,042$421,546.65$78,586$28,686.63+$1.26MNRBO
10$2,045,428$615,863.14$144,688$63,430.49+$1.90MNRBO

NRBO vs PEP: Complete Analysis 2026

NRBOStock

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Full NRBO Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this NRBO vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NRBO vs SCHDNRBO vs JEPINRBO vs ONRBO vs KONRBO vs MAINNRBO vs MONRBO vs PMNRBO vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.